Pixium Vision - Strategy in place to mitigate COVID-19 effects
Pixium recently made prudent operational changes to contain expenditures while keeping the long-term investment thesis intact during the COVID-19 pandemic. With the feasibility studies paused and the start of a pivotal study possibly pushed to 2021, we expect these and other cost-cutting initiatives to enable Pixium to maintain its operations into late 2020. These actions should position the firm well to resume normal operations once the COVID-19 situation improves.Pixium Vision SA is a company that specializes in sensorial neuromodulation. Co. is also collaborating with scientific groups and clinicians at research institutes and clinical centers around the world, including Stanford University (USA). Co. is developing and aims to commercialize Bionic Vision Systems (BVS) – namely active implantable medical devices to treat blindness caused by degeneration of photoreceptor cells in the retina.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.